Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (USD $)	Cocrystal Discovery, Inc. Series A Convertible Preferred Stock	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock	Additional Paid-In Capital	Accumulated other comprehensive income [Member]	Accumulated Deficit	Total
Beginning balance at Dec. 31, 2012	$ 10,108,000				$ 3,440,000		$ (8,448,000)	$ (5,008,000)us-gaap_StockholdersEquity
Beginning balance, shares at Dec. 31, 2012	7,046		279
Issuance of series A preferred stock
Stock based compensation					55,000			55,000
Exercise of stock options					7,000			7,000
Net loss							(3,887,000)	(3,887,000)us-gaap_NetIncomeLoss
Ending balance at Dec. 31, 2013	10,108,000				3,502,000		(12,335,000)	(8,833,000)us-gaap_StockholdersEquity
Ending balance, shares at Dec. 31, 2013	7,046		279					0us-gaap_CommonStockSharesIssued
Stock based compensation					38,000			38,000
Conversion of series A convertible stock, Amount	(10,108,000)		1,000		10,107,000			10,108,000
Conversion of series A convertible stock, Shares	(7,046)		721
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Amount				116,000	(1,596,000)			(1,480,000)
Merger between Biozone Pharmaceuticals, Inc. and Cocrystal Discovery, Inc., Shares				115,907
Exercise of common stock options, Amount				1,000	115,000			116,000cocp_ExerciseOfCommonStockOptionsAmount
Exercise of common stock options, Shares				1,087
Issuance of common stock and warrants in January 2014, Amount				6,000	(6,000)
Issuance of common stock and warrants in January 2014, Shares				5,500
Unrealized gain on marketable securities, net of tax						236,000		236,000
Series A preferred stock issued in the merger with RFS Pharm, LLC, Amount		178,218,000
Series A preferred stock issued in the merger with RFS Pharm, LLC, Shares		1,000
Stock options issued in the merger with RFS Pharm, LLC					6,565,000			6,565,000
Net loss							(99,000)	(99,000)us-gaap_NetIncomeLoss
Ending balance at Dec. 31, 2014		$ 178,218,000	$ 1,000	$ 123,000	$ 18,725,000	$ 236,000	$ (12,434,000)	$ 6,651,000us-gaap_StockholdersEquity
Ending balance, shares at Dec. 31, 2014		1,000	1,000	122,494				122,494us-gaap_CommonStockSharesIssued